Chemical library screening approaches to aid the design of protein-protein inhibitors

Understanding and Exploiting Protein-Protein Interactions as Drug Targets

Volumn , Issue , 2013, Pages 33-45

  Laraia, Luca ^a   Spring, David R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN COMPUTER INTERACTION;

CHEMICAL LIBRARIES; PROTEIN INHIBITORS;

PROTEINS;

EID: 84957056857     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4155/EBO.13.151     Document Type: Chapter

References (21)

1. Miyazaki M, Kawato H, Naito H et al. Discovery of novel dihydroimidazothiazole derivatives as p53/MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships. Bioorg. Med. Chem. Lett. 22(20), 6338-6342 (2012).
2. Perez HL, Banafi P, Bertrand J et al. Identification of a phenylacylsulfonamide series of dual BCL-2/BCL-xL antagonists. Bioorg. Med. Chem. Lett. 22(12), 3946-3950 (2012).
3. Rew Y et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem. 55(11), 4936-4954 (2012).
4. Zhou H, Aguilar A, Chen J et al. Structure-based design of potent BCL-2/BCL-xL inhibitors with strong in vivo antitumor activity. J. Med. Chem. 55(13), 6149-6161 (2012).
5. Zhuang C, Miao Z, Zhu L et al. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. J. Med. Chem. 55(22), 9630-9642 (2012).
6. Furet P, Chene P, De Pover A et al. The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. Bioorg. Med. Chem. Lett. 22(10), 3498-3502 (2012).
7. Gandhi L, Camidge DR, Ribeiro de Oliveira M et al. Phase I study of navitoclax (ABT-263), a novel BCL-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Onc. 29(7), 909-916 (2011).
8. Bourgeas RL, Basse MJ, Morelli X, Roche P. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PLoS ONE, 5(3), e9598 (2010).
9. Morelli X, Bourgeas RL, Roche P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 15(4), 475-481 (2011).
10. Shi A, Murai MJ, He S et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120(23), 4461-4469 (2012).
11. Tsiang M, Jones GS, Niedziela- Majka A et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J. Biol. Chem. 287(25), 21189-21203 (2012).
12. Baell JB, Holloway GA. New substructure filters for removal of Pan Assay Interference Compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53(7), 2719-2740 (2010).
13. O' Connor CJ, Beckmann HSG, Spring DR. Diversity-oriented synthesis: producing chemical tools for dissecting biology. Chem. Soc. Rev. 41(12), 4444-4456 (2012).
14. Marcaurelle LA, Johannes C, Yohannes D, Tillotson BP, Mann D. Diversity-oriented synthesis of a cytisine- inspired pyridone library leading to the discovery of novel inhibitors of BCL-2. Bioorg. Med. Chem. Lett. 19(9), 2500-2503 (2009).
15. Clemons PA, Bodycombe NE, Carrinski HA et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profi es. Proc. Natl Acad. Sci. USA 107(44), 18787-18792 (2010).
16. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52(21), 6752-6756 (2009).
17. Dancik V, Seiler KP, Young DW et al. Distinct biological network properties between the targets of natural products and disease genes. J. Am. Chem. Soc. 132(27), 9259-9261 (2010).
18. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4(3), 206-220 (2005).
19. Rose R, Erdmann S, Bovens S et al. Identification and structure of small-molecule stabilizers of 14-3-3 protein- protein interactions. Angew. Chem. Int. Ed. 49(24), 4129-4132 (2011).
20. Wetzel S, Robin S Bon, Kumar K et al. Biology- oriented synthesis. Angew. Chem. Int. Ed. 50(46), 10800-10826 (2011).
21. Marsault E, Peterson ML. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54(7), 1961-2004 (2011).